MED 27Alternative Names: Medosan 27
Latest Information Update: 11 Oct 2006
At a glance
- Originator sigma-tau SpA
- Class Antiplatelets
- Mechanism of Action Thromboxane receptor antagonists; Thromboxane synthase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 11 Oct 2006 Discontinued - Phase-I for Thrombosis in Italy (unspecified route)